Opus Genetics Reports Positive Data From Two Gene Therapy Programs
In the initial low-dose Cohort 1 of its Phase 1/2 trial, OPGx-BEST1 improved retinal sensitivity in 75% of evaluable participants. The company also reported new analyses linking BEST1 retinal structure to visual function.